These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 7685840)
41. Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment. Kubota Y; Yanai H; Sasagawa I; Suzuki H; Nakada T; Sugano O Int Urol Nephrol; 1996; 28(3):349-55. PubMed ID: 8899475 [TBL] [Abstract][Full Text] [Related]
42. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. Csapo Z; Brand K; Walther R; Fokas K J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419 [TBL] [Abstract][Full Text] [Related]
43. Histochemical study of R1881-binding protein, prostatic acid phosphatase, prostate-specific antigen, and r-seminoprotein in prostatic cancer. Ito H; Yamaguchi K; Sumiya H; Matsuzaki O; Shimazaki J Eur Urol; 1986; 12(1):49-53. PubMed ID: 2419136 [TBL] [Abstract][Full Text] [Related]
44. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459 [TBL] [Abstract][Full Text] [Related]
45. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer]. Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237 [TBL] [Abstract][Full Text] [Related]
46. [Prostate specific antigen in serum of the patients with prostatic cancer]. Akimoto S; Akakura K; Fuse H; Shimazaki J Hinyokika Kiyo; 1988 Apr; 34(4):636-42. PubMed ID: 2456678 [TBL] [Abstract][Full Text] [Related]
47. [The role of PSA in diagnosis of prostate cancer and its recurrence]. Vergho DC; Heine K; Wolff JM Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709 [TBL] [Abstract][Full Text] [Related]
48. [Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma]. Kakinuma H; Sasaki R; Sato K; Hirano S; Miura K; Sasaki S; Kato T Nihon Hinyokika Gakkai Zasshi; 1996 Jul; 87(7):997-1003. PubMed ID: 8776967 [TBL] [Abstract][Full Text] [Related]
49. Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer. Akakura K; Akimoto S; Shimazaki J J Cancer Res Clin Oncol; 1996; 122(10):633-7. PubMed ID: 8879262 [TBL] [Abstract][Full Text] [Related]
50. [Efficacy of long-term monitoring of markers of prostate cancer, with special reference to gamma-Sm and PAP]. Yonese Y; Ishikawa S; Tozuka K; Goto K Rinsho Byori; 1986 Jul; 34 Spec No 68():106-12. PubMed ID: 3761646 [No Abstract] [Full Text] [Related]
51. [The changes of serum gamma-Sm level in acute prostatitis]. Fujimoto K; Kodaira T Nihon Hinyokika Gakkai Zasshi; 1990 Nov; 81(11):1675-9. PubMed ID: 2287114 [TBL] [Abstract][Full Text] [Related]
52. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850 [TBL] [Abstract][Full Text] [Related]
53. [Clinical evaluation of gamma-seminoprotein as a serum marker of prostate carcinoma]. Sugimura Y; Sakurai M; Hioki T; Hayashi N; Yamakawa K; Tajima K; Tochigi H; Kawamura J Hinyokika Kiyo; 1988 Dec; 34(12):2129-34. PubMed ID: 2467541 [TBL] [Abstract][Full Text] [Related]
54. The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer. van Dieijen-Visser MP; Hendriks MW; Delaere KP; Gijzen AH; Brombacher PJ Clin Chim Acta; 1988 Sep; 177(1):77-80. PubMed ID: 2460272 [TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828 [TBL] [Abstract][Full Text] [Related]
57. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740 [TBL] [Abstract][Full Text] [Related]
58. [Diagnosis of prostate cancer by means of the ratio of prostate specific antigen/gamma-seminoprotein (P/S ratio)]. Demura T; Ohyama I; Togashi M; Ohashi N; Chikaraishi T; Hirano T; Koyanagi T Nihon Hinyokika Gakkai Zasshi; 1994 May; 85(5):731-7. PubMed ID: 7517468 [TBL] [Abstract][Full Text] [Related]
59. PSA and PAP as immunohistochemical markers in prostate cancer. Epstein JI Urol Clin North Am; 1993 Nov; 20(4):757-70. PubMed ID: 7505984 [TBL] [Abstract][Full Text] [Related]
60. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Bertagna C; De Géry A; Hucher M; François JP; Zanirato J Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]